BCL2 and malignant glioma: Additional strategies to target Bcl-2 family proteins, not all of which have been tested in malignant glioma, include antisense approaches and diverse compounds such as tetrocarcin A (TC-A), antimycin A3, chelerythrine, and WP1066 [44, 45].